Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCC NASDAQ:MBIO NASDAQ:PHXM NASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$1.93-2.0%$2.59$1.29▼$7.12$10.34M2.1969,924 shs15,826 shsMBIOMustang Bio$1.58$1.80$0.89▼$21.95$11.44M2.23113,182 shs113,979 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/APRFXPainReform$1.34-5.6%$1.47$1.25▼$16.63$2.86M0.578.83 million shs160,119 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis0.00%0.00%-25.94%-12.83%-13.97%MBIOMustang Bio0.00%+10.49%-10.73%+42.34%-88.30%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%PRFXPainReform0.00%0.00%+5.19%-19.77%-59.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCCIM Cannabis$1.93-2.0%$2.59$1.29▼$7.12$10.34M2.1969,924 shs15,826 shsMBIOMustang Bio$1.58$1.80$0.89▼$21.95$11.44M2.23113,182 shs113,979 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/APRFXPainReform$1.34-5.6%$1.47$1.25▼$16.63$2.86M0.578.83 million shs160,119 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCCIM Cannabis0.00%0.00%-25.94%-12.83%-13.97%MBIOMustang Bio0.00%+10.49%-10.73%+42.34%-88.30%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%PRFXPainReform0.00%0.00%+5.19%-19.77%-59.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCCIM Cannabis 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/APRFXPainReform 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCCIM Cannabis$39.44M0.26N/AN/A$1.03 per share1.87MBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/APRFXPainReformN/AN/AN/AN/A$2.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCCIM Cannabis-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/12/2025 (Estimated)MBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-29.49%11/6/2025 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/APRFXPainReform-$14.59M-$147.33N/A∞N/AN/AN/AN/A9/18/2025 (Estimated)Latest PRFX, PHXM, IMCC, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025IMCCIM Cannabis-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 million8/8/2025Q2 2025MBIOMustang BioN/A-$0.19N/A-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCCIM CannabisN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCCIM Cannabis0.320.720.62MBIOMustang BioN/A1.301.30PHXMPHAXIAM Therapeutics0.231.78N/APRFXPainReformN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCCIM Cannabis7.68%MBIOMustang Bio9.95%PHXMPHAXIAM Therapeutics0.40%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipIMCCIM CannabisN/AMBIOMustang Bio0.21%PHXMPHAXIAM Therapeutics1.94%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCCIM Cannabis3405.25 millionN/ANot OptionableMBIOMustang Bio1007.24 million7.23 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataPRFXPainReform42.01 million1.32 millionNot OptionablePRFX, PHXM, IMCC, and MBIO HeadlinesRecent News About These CompaniesPainReform’s DeepSolar accepted into Nvidia Connect ProgramAugust 19, 2025 | msn.comPainReform’s DeepSolar Joins NVIDIA Connect Program to Enhance Solar ForecastingAugust 19, 2025 | msn.comNvidia enrollment sends this stock soaring 130%August 19, 2025 | finbold.comFTop Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug August 19, 2025 | rttnews.comPainReform Ltd.'s DeepSolar Enters NVIDIA Connect Program to Enhance AI-Driven Solar Forecasting SolutionsAugust 19, 2025 | quiverquant.comQPainReform/DeepSolar Accepted into NVIDIA Connect ProgramAugust 19, 2025 | globenewswire.comPainReform Enters Cataract Surgery Market with LayerBio InvestmentAugust 14, 2025 | msn.comPainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug ...August 13, 2025 | uk.finance.yahoo.comPainReform completes strategic investment in LayerBioAugust 13, 2025 | msn.comPainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery SystemAugust 13, 2025 | globenewswire.comPainreform stock falls after announcing strategic investment in ...July 11, 2025 | investing.comPainReform invests in LayerBio to expand into ophthalmologyJuly 11, 2025 | investing.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand ...July 11, 2025 | seekingalpha.comPainreform stock falls after announcing strategic investment in LayerBioJuly 10, 2025 | au.investing.comPainreform Shares Drop 11% After Revealing Strategic Stake in LayerBioJuly 10, 2025 | msn.comPainReform Expands into Ophthalmology with Strategic Investment in LayerBioJuly 10, 2025 | tipranks.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...July 10, 2025 | gurufocus.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...July 10, 2025 | gurufocus.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBioJuly 10, 2025 | globenewswire.comBlade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software SalesMay 27, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRFX, PHXM, IMCC, and MBIO Company DescriptionsIM Cannabis NASDAQ:IMCC$1.93 -0.04 (-2.03%) Closing price 03:59 PM EasternExtended Trading$1.87 -0.06 (-3.11%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.Mustang Bio NASDAQ:MBIO$1.58 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.32%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 09/12/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.PainReform NASDAQ:PRFX$1.34 -0.08 (-5.63%) Closing price 03:59 PM EasternExtended Trading$1.34 +0.00 (+0.37%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
